Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gastric Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 20 articles: HTML format

Single Articles

May 2025
1. ROSANU NM, Gervaso L, Cella CA, Fazio N, et al
   Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer.
   Eur J Cancer. 2025;224:115521.
   PubMed     Abstract available
   
   
   March 2025
2. KAMP D, May AM, Adenis A, Capela A, et al
   Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study.
   Eur J Cancer. 2025;218:115278.
   PubMed     Abstract available
   
   
   
3. SATOH T, Barthelemy P, Nogova L, Honda K, et al
   Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.
   Eur J Cancer. 2025;218:115262.
   PubMed     Abstract available
   
   
   February 2025
4. ISHIDA H, Sunakawa Y, Kodera Y, Yoshida K, et al
   Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study.
   Eur J Cancer. 2025;219:115322.
   PubMed     Abstract available
   
   
   November 2024
5. GEERTS JFM, Pape M, Vissers PAJ, Verhoeven RHA, et al
   Patient access to perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with resectable gastric cancer in the Netherlands.
   Eur J Cancer. 2024;214:115137.
   PubMed     Abstract available
   
   
   October 2024
6. FUJITANI K, Kurokawa Y, Wada R, Takeno A, et al
   Prospective single-arm multicenter interventional study of surgical resection for liver metastasis from gastric cancer; 3-year overall and recurrence-free survival.
   Eur J Cancer. 2024;213:115080.
   PubMed     Abstract available
   
   
   
7. SCHIRIZZI A, Donghia R, De Nunzio V, Renna N, et al
   High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma.
   Eur J Cancer. 2024;213:115066.
   PubMed     Abstract available
   
   
   June 2024
8. KROESE TE, Bronzwaer S, van Rossum PSN, Schoppman SF, et al
   European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
   Eur J Cancer. 2024;204:114062.
   PubMed     Abstract available
   
   
   May 2024
9. RAIMONDI A, Kim YW, Kang WK, Langley RE, et al
   Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
   Eur J Cancer. 2024;203:114043.
   PubMed     Abstract available
   
   
   April 2024
10. DIERKS S, Buchholz SM, Konig A, Liersch T, et al
    Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.
    Eur J Cancer. 2024;204:114076.
    PubMed    
    
    
    January 2024
11. ZHAO P, Li S, Du X
    Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer: A long way to go.
    Eur J Cancer. 2024;199:113554.
    PubMed    
    
    
    
12. VAN DER SLUIS K, Taylor SN, Kodach LL, van Dieren JM, et al
    Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: A nationwide study.
    Eur J Cancer. 2024;199:113541.
    PubMed     Abstract available
    
    
    December 2023
13. TAIEB J, Bennouna J, Penault-Llorca F, Basile D, et al
    Treatment of gastric adenocarcinoma: A rapidly evolving landscape.
    Eur J Cancer. 2023;195:113370.
    PubMed     Abstract available
    
    
    September 2023
14. AIX PONCE S, Cousin S, Dubos P, Belcaid L, et al
    Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Eur J Cancer. 2023;193:113309.
    PubMed    
    
    
    
15. MUTI HS, Rocken C, Behrens HM, Loffler CML, et al
    Deep learning trained on lymph node status predicts outcome from gastric cancer histopathology: a retrospective multicentric study.
    Eur J Cancer. 2023;194:113335.
    PubMed     Abstract available
    
    
    July 2023
16. KALFF MC, Dijksterhuis WPM, Wagner AD, Oertelt-Prigione S, et al
    Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
    Eur J Cancer. 2023;187:114-123.
    PubMed     Abstract available
    
    
    June 2023
17. ASPLUND JPU, Mackenzie HA, Markar SR, Lagergren JHF, et al
    Surgeon proficiency gain and survival after gastrectomy for gastric adenocarcinoma: A population-based cohort study.
    Eur J Cancer. 2023;186:91-97.
    PubMed     Abstract available
    
    
    
18. JIA K, Chen Y, Xie Y, Chong X, et al
    Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.
    Eur J Cancer. 2023;189:112931.
    PubMed     Abstract available
    
    
    April 2023
19. PORTH I, Hirsch D, Ceribas Y, Weidner P, et al
    Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Eur J Cancer. 2023;183:119-130.
    PubMed     Abstract available
    
    
    February 2023
20. KAWAKAMI H, Sunakawa Y, Inoue E, Matoba R, et al
    Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
    Eur J Cancer. 2023;184:10-20.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.